ProQR (PRQR) Price & Analysis

Compare

1,149 Followers

PRQR Stock Chart & Stats

$2.33

-$0.10(-3.77%)

At close: Jan 08 4:00 PM EST

$2.33

-$0.10(-3.77%)

Day’s Range― - ―

52-Week Range$1.07 - $3.27

Previous CloseN/A

Volume75.97K

Average Volume (3M)534.76K

Market Cap

$250.41M

Enterprise Value$91.96M

Total Cash (Recent Filing)$106.88M

Total Debt (Recent Filing)$16.49M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Feb 19, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding105,212,524

10 Day Avg. Volume796,312

30 Day Avg. Volume534,757

Financial Highlights & Ratios

PEG Ratio2.63

Price to Book (P/B)2.36

Price to Sales (P/S)11.05

P/FCF Ratio-5.53

Enterprise Value/Market Cap0.37

Enterprise Value/Revenue5.91

Enterprise Value/Gross Profit5.91

Enterprise Value/Ebitda-2.43

Forecast

1Y Price Target

$7.25

Price Target Upside211.16% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market ValuationProQR is seen as significantly undervalued compared to other RNA editing peers, especially given its wholly owned pipeline and active clinical program with AX-0810.

Platform ValidationAX-0810's Phase 1 readout has the potential to validate ProQR’s Axiomer platform in humans and open expansion opportunities into broader fibrotic and metabolic diseases.

Strategic PartnershipsThe partnership with Eli Lilly provides external validation for ProQR, enhancing its credibility and potential in the market.

Bears Say

Durability ConcernsThere is a need for long-term monitoring to provide confidence in the durability of editing and to rule out potential immune activation.

ProQR News

Positive Outlook for ProQR’s AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy Recommendation

Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on ProQR. The associated price target remains...

4d ago

PRQR

ProQR Therapeutics Reports Q3 2025 Financial Results

ProQR Therapeutics BV ( ($PRQR) ) has released its Q3 earnings. Here is a breakdown of the information...

23d ago

PRQR

ProQR Reports Q3 2025 Financial Results Amid Revenue Decline

ProQR ( ($PRQR) ) just unveiled an update. ProQR Therapeutics N.V. announced its financial results for the third...

1M ago

PRQR

ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year

Reports Q3 revenue EUR 2.882M vs EUR 3.843M last year. “Last month we achieved an important milestone with...

1M ago

PRQR

ProQR Positioned for Growth: Strategic Advancements and Clinical Milestones in RNA Editing

Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR and keeping the price target at...

1M ago

PRQR

ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases

ProQR ( ($PRQR) ) has issued an announcement. On November 3, 2025, ProQR Therapeutics hosted a virtual analyst...

1M ago

PRQR

PRQR Upcoming Earnings Report: What to Expect?

ProQR Therapeutics BV (PRQR) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street...

1M ago

PRQR

ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event

ProQR ( ($PRQR) ) has shared an announcement. On October 20, 2025, ProQR Therapeutics announced that it received...

2M ago

PRQR

ProQR Therapeutics receives CTA authorization for AX-0810

ProQR Therapeutics (PRQR) announced that following review under the new European Medicines Agency, EMA, centralized review process, the...

2M ago

PRQR

ProQR Therapeutics management to meet with Citizens JMP

Meeting to be held in New York on October 20 hosted by Citizens JMP. Published first on TheFly...

2M ago

PRQR

ProQR Therapeutics Advances RNA Therapy Pipeline

ProQR Therapeutics BV ( ($PRQR) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

PRQR

ProQR’s Strategic Advancements and Promising RNA Editing Platform Earns Buy Rating

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR, with a...

4M ago

PRQR

ProQR’s Strategic Advancements and Clinical Prospects Drive Buy Rating

In a report released on August 8, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ProQR,...

4M ago

PRQR

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

Reports revenue EUR 3.8M vs. EUR 6.3M last year. “We continued to execute across our pipeline in the...

4M ago

PRQR

PRQR FAQ

What was ProQR’s price range in the past 12 months?

ProQR lowest stock price was $1.07 and its highest was $3.27 in the past 12 months.

What is ProQR’s market cap?

ProQR’s market cap is $250.41M.

When is ProQR’s upcoming earnings report date?

ProQR’s upcoming earnings report date is Feb 19, 2026 which is in 67 days.

How were ProQR’s earnings last quarter?

ProQR released its earnings results on Nov 06, 2025. The company reported -$0.117 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.001.

Is ProQR overvalued?

According to Wall Street analysts ProQR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProQR pay dividends?

ProQR does not currently pay dividends.

What is ProQR’s EPS estimate?

ProQR’s EPS estimate is -0.12.

How many shares outstanding does ProQR have?

ProQR has 105,212,524 shares outstanding.

What happened to ProQR’s price movement after its last earnings report?

ProQR reported an EPS of -$0.117 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went down -7.143%.

Which hedge fund is a major shareholder of ProQR?

Currently, no hedge funds are holding shares in PRQR

ProQR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-99.45%

Trailing 12-Months

Asset Growth

27.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ProQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR (PRQR) Earnings & Revenues

Historic Earnings Reports

PRQR Stock 12 Month Forecast

Average Price Target

$7.25

▲(211.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.88,3.6399999999999997,4.4,5.16,5.92,6.68,7.4399999999999995,8.2,8.959999999999999,9.719999999999999,10.48,11.239999999999998,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.514615384615385,2.9092307692307693,3.3038461538461537,3.6984615384615385,4.093076923076923,4.487692307692308,4.882307692307692,5.276923076923077,5.671538461538462,6.066153846153846,6.46076923076923,6.855384615384615,{"y":7.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.264615384615385,2.4092307692307693,2.553846153846154,2.6984615384615385,2.8430769230769233,2.987692307692308,3.1323076923076925,3.276923076923077,3.4215384615384616,3.5661538461538465,3.710769230769231,3.8553846153846156,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >